Orthocell Ltd. (ASX:OCC) Secures A$3.18 Million R&D Refund and Strengthens Global Market Position

3 min read | January 20, 2025 01:43 PM AEDT | By Team Kalkine Media

Google News:

Orthocell Ltd. (ASX:OCC) Secures A$3.18 Million R&D Refund and Strengthens Global Market Position — Image source: shutterstock

Recent News

Is Computershare (ASX:CPU) A Financial Services Gauge?

Why Is Westpac (ASX:WBC) Back In Bank Focus?

What Puts ANZ (ASX:ANZ) On Financial Screens?

What Makes NDQ (ASX:NDQ) A Tech ETF Test?

Make Kalkine Media
My Trusted Source

Highlights

Orthocell Ltd. (ASX:OCC) receives a A$3.18 million R&D tax refund, boosting its cash reserves to A$33 million.

The company is preparing for a US market entry with its innovative medical devices.

A strategic global expansion is underway, including successful product clearances and promising growth potential.

Orthocell Ltd. (ASX:OCC), a leader in regenerative medicine, has strengthened its position in the global healthcare market by securing a substantial A$3.18 million research and development (R&D) tax refund from the Australian Government. This addition increases the company’s cash reserves to an impressive A$33 million, further fortifying its war chest as it advances its commercialization strategy worldwide.

Orthocell specializes in the repair of bone and soft tissue injuries through its innovative CelGro™ platform. The company focuses on collagen medical devices that facilitate tissue reconstruction and healing for both dental and orthopaedic applications. Its products, including the breakthrough Striate+™, Remplir™, and SmrtGraft™, demonstrate considerable potential in the expanding regenerative medicine sector.

A major milestone for Orthocell is its entry into the U.S. market. The company is on track for FDA clearance, positioning itself to introduce Remplir™ to the U.S. market in late March or early April 2025. Orthocell CEO, Paul Anderson, expressed excitement about the opportunity, emphasizing the significant growth the U.S. market—valued at US$1.6 billion—offers to the company. With a strong pipeline and revenue growth already evident in existing markets, Orthocell Ltd. expects this next phase of expansion to significantly increase its revenue potential.

Orthocell’s offerings have also earned clearance across several international markets. Striate+™ has already received approval for dental guided bone regeneration (GBR) applications in key markets, including the U.S. (510k), Canada (MDL), and Europe (CE Mark). The company is also expanding the clinical availability of its tendon repair product, SmrtGraft™, in Australia under Special Access schemes and clinical trials, while Remplir™ is already approved in Australia, New Zealand, and Singapore.

Another exciting development lies within the company’s autologous cell therapies aimed at regenerating damaged tendon and cartilage tissue. The ongoing acceleration of the tendon cell therapy program in the U.S. and engagement with the FDA signals Orthocell’s commitment to unlocking future commercial opportunities in this lucrative space.

With a strong foundation, an expanding product portfolio, and strategic focus on high-growth international markets, Orthocell Ltd. is positioning itself for significant achievements in the global medical device market.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.